

1 Article

2 Synthesis and *in vitro* Antibacterial Activity of 3 Quaternization 10-Methoxycanthin-6-one Derivatives

4 Na Li ¹, Jiang-Kun Dai ², Dan Liu ², Jin-Yi Wang ^{1,2,*} and Jun-Ru Wang ^{2,*}

5 ¹ Colleges of Veterinary Medicine, Northwest A&F University, Yangling, Shaanxi 712100, China;

6 lnuk@nwsuaf.edu.cn (N.L.); jywang@nwsuaf.edu.cn (J.-Y. W.);

7 ² Colleges of Chemistry and Pharmacy, Northwest A&F University, Yangling, Shaanxi 712100, China;

8 daijkun@hotmail.com (J.-K.D.); ld127222@126.com (D.-R. W.); wangjunru@nwafu.edu.cn (J.-R. W.)

9 * Correspondence: wangjunru@nwafu.edu.cn (J.-R. W.); jywang@nwsuaf.edu.cn (J.-Y. W.);

10

11

12 **Abstract:** Natural products are an important source of antibacterial agents. Canthin-6-one alkaloids
13 have displayed potential antibacterial activity based on our previous work. In order to improve the
14 activity, twenty-two new 3-N-benzylated 10-methoxy canthin-6-ones were designed and
15 synthesized through quaternization reaction. The *in vitro* antibacterial activity against three
16 bacteria was evaluated by double dilution method. Four compounds (**6f**, **6i**, **6p** and **6t**) displayed
17 2-fold superiority (minimum inhibitory concentration (MIC) = 3.91 µg/mL) against agricultural
18 pathogenic bacteria *R. solanacearum* and *P. syringae* than agrochemical propineb. Moreover, the
19 structure–activity relationships (SARs) were also carefully summarized in order to guide the
20 development of antibacterial canthin-6-one agents.

21 **Keywords:** 10-methoxycanthin-6-one; quaternization; antibacterial; SARs

22

23 1. Introduction

24 Healthcare systems, farming, and the food production industry are the main sectors driving
25 antibiotic consumption [1]. To maintain animal welfare and food security, there are many
26 circumstances where antibiotics are required in farming and food production, including for
27 livestock, poultry, aquaculture, and crops [2–5]. *Bacillus cereus* could cause food poisoning [6].
28 *Ralstonia solanacearum* and *Pseudomonas syringae* are major components of plant pathogens [7]. We
29 could see that all of these diseases caused by bacteria constitute a major threat to humans' life and
30 property. Antibiotics have a massive impact on both health and society. Yet we are in increasing
31 danger of losing them because the efforts of pharmaceutical industry are channeled towards some




Figure 1. Design of the quaternization 10-methoxycanthin-6-one analogues.

diseases that have more favorable prospects for a return on investment [8]. Therefore, we need to develop new candidates to enrich the types of antibacterial agents and provided more options for solving the issue of “lack of antibiotics”.


Natural products, millions of years of evolution, are fashioned by natural selection to interact with cellular targets with high efficiency and selectivity and to avoid resistance. Specially, they are privileged in the sphere of antibiotic development [8,9]. About 200 natural products were directly used as antibiotic drugs and improvements by semi-synthesis on these scaffolds generated another 200–300 drugs [8,9].

Canthin-6-one **1**, mainly from the Rutaceae and Simaroubaceae families, are a subclass of the tryptophan-derived β -carboline alkaloids [10,11]. In our previous work, we found that quaternization modification could significantly improve the antibacterial activity (Figure 1) [12,13]. For example, the antibacterial activity of compounds **2** and **4** against *B. cereus* enhanced 2-fold and 8-fold, respectively. Interestingly, 10-methoxycanthin-6-one **5**, *per se* has good antibacterial activity [14,15]. With the aim of finding more promising antibacterial canthin-6-one analogues, we report here a simple idea and design to generate the bioactive compounds by quaternization reaction of 10-methoxycanthin-6-one.

2. Results and Discussion

2.1. Chemistry

The synthetic route of target compounds **6a–6v** was outlined in Scheme 1. The natural product 10-methoxycanthin-6-one **5** could be easily obtained by sequentially Borch reduction, Pictet-Spengler reaction, catalytic hydrogen transfer reaction and oxidation reaction [15]. With this



No.	R	X	No.	R	X	No.	R	X

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

6a	-CH ₂ Ph(<i>o</i> -F)	Br	6i	-CH ₂ Ph(<i>m</i> -Me)	Br	6q	-CH ₂ Ph(<i>o</i> -Br)	Br
6b	-CH ₂ Ph(<i>p</i> -F)	Br	6j	-CH ₂ Ph(<i>m</i> -OMe)	Cl	6r	-CH ₂ Ph(<i>p</i> -Br)	Br
6c	-CH ₂ Ph(<i>m</i> -F)	Br	6k	-CH ₂ Ph(<i>o</i> -CF ₃)	Br	6s	-CH ₂ Ph(<i>m</i> -Br)	Br
6d	-CH ₂ Ph(<i>m</i> -CN)	Cl	6l	-CH ₂ Ph(<i>p</i> -CF ₃)	Br	6t	-CH ₂ Ph(<i>m</i> -I)	Br
6e	-CH ₂ Ph(<i>o</i> -Cl)	Cl	6m	-CH ₂ Ph(<i>m</i> -CF ₃)	Br	6u	-CH ₂ Ph	Br
6f	-CH ₂ Ph(<i>m</i> -Cl)	Cl	6n	-CH ₂ Ph(2,5-difluoro)	Br	6v	-CH ₂ Ph	Cl
6g	-CH ₂ Ph(<i>o</i> -Me)	Br	6o	-CH ₂ Ph(2,4-difluoro)	Br			
6h	-CH ₂ Ph(<i>p</i> -Me)	Br	6p	-CH ₂ Ph(3,4-dichloro)	Br			

56 **Scheme1.** Synthetic route and chemical structures of compounds **5** and **6a–6v**. Reagents and
 57 conditions: (a) i: benzaldehyde, MeOH, r.t.; ii: NaBH₄, r.t., 98%; (b) α -ketoglutaric acid, *p*-TSA, dry
 58 toluene:dioxane = 3:2, DST, reflux, 83%; (c) HCOONH₄, 5% Pd/C, MeOH:toluene = 1:1, heated, 75%;
 59 (d) 5% Pd/C, xylene, reflux, 90%;(e) CH₃CN, reflux, r.t., 42–72%.

60 compound **5** in hand, attention was focused on modifying the 3-N position. Benzyl group in this
 61 position significantly increased the activity (**Figure 1**). So we synthesized a series of quaternization
 62 10-methoxycanthin-6-one derivatives **6a–6v** (42–72% yields) with diverse substituted benzyl group
 63 which varied in electron-inducing ability and substitution position.

64 All the structures of the target compounds (**5** and **6a–6v**) were confirmed by ¹H NMR, ¹³C
 65 NMR and HRMS spectra. In the NMR spectra of compound **6a**, the signal of the methylene group
 66 was detected around $\delta = 6.39$ ppm and $\delta = 56.4$ ppm, respectively, which indicated that the
 67 quaternization 10-methoxycanthin-6-one derivatives were successfully synthesized. Moreover, the
 68 signal of [M–Br]⁺ could be found at 359.1189 Da in HRMS spectra of compound **6a** (error = 0.28
 69 ppm), which conformed to the theoretical value 359.1190 Da within the allowable error range (error
 70 < 5 ppm).

71 2.2. Antibacterial Activity

72 The *in vitro* antibacterial activity of compounds **5** and **6a–6v** were evaluated against three kinds
 73 of bacteria (*B. cereus*, *R. solanacearum* and *P. syringae*) using the double dilution method giving the
 74 MIC values [16]. Fosfomycin sodium and agrochemical propineb were used as the positive controls
 75 [14,17]. The antibacterial results (**Table 1**) revealed that most of the quaternization
 76 10-methoxycanthin-6-one derivatives displayed good *in vitro* biological activity against *R.*
 77 *solanacearum* and *P. syringae* compared with agrochemical propineb. Similar result was also
 78 proposed by Bazina *et al.* [18]. Eight compounds (**6e**, **6f**, **6i**, **6k**, **6l**, **6m**, **6p** and **6t**) displayed 4-fold
 79 superiority (MIC = 3.91 μ g/mL) against *R. solanacearum* than lead compound **5** and 2-fold superiority
 80 than propineb. Five compounds (**6f**, **6h**, **6i**, **6p** and **6t**) displayed 2-fold superiority (MIC = 3.91
 81 μ g/mL) against *P. syringae* than lead compound **5** and propineb. Unfortunately, quaternization
 82 modification did not improve the activity for *B. cereus*. It is worth mentioning that four compounds
 83 (**6p**, **6q**, **6r** and **6t**) still have potential antibacterial activity against *B. cereus* compared with natural
 84 canthin-6-one **1**. Overall, compounds **6p** and **6t** were considered to be the highly active derivatives
 85 against these three bacteria.

Table 1. Antibacterial activity of compounds **6a–6v** against three bacteria (MIC, μ g/mL).

No.	<i>B. cereus</i>	<i>R. solanacearum</i>	<i>P. syringae</i>	No.	<i>B. cereus</i>	<i>R. solanacearum</i>	<i>P. syringae</i>
6a	15.63	15.63	15.63	6n	31.25	7.81	15.63
6b	15.63	15.63	15.63	6o	15.63	15.63	7.81
6c	31.25	7.81	15.63	6p	7.81	3.91	3.91

6d	62.50	15.63	15.63	6q	7.81	7.81	15.63
6e	15.63	3.91	7.81	6r	7.81	7.81	7.81
6f	15.63	3.91	3.91	6s	15.63	7.81	7.81
6g	15.63	7.81	7.81	6t	7.81	3.91	3.91
6h	15.63	7.81	3.91	6u	15.63	15.63	15.63
6i	15.63	3.91	3.91	6v	15.63	15.63	15.63
6j	15.63	15.63	7.81	5	3.91	15.63	7.81
6k	15.63	3.91	7.81	F.S. ^a	3.91	-	-
6l	15.63	3.91	7.81	P. ^a	3.91	7.81	7.81
6m	15.63	3.91	15.63				

^a Fosfomycin sodium; Propineb.

86 2.3. Structure–activity relationships

87 Based on the antibacterial activity data, the structure–activity relationships were carefully
 88 investigated for *R. solanacearum* and *P. syringae*. Halogen anion did not affect the activity. For
 89 example, the antibacterial activity of compounds **6u** and **6v** are equal. The substituted benzyl groups
 90 are favorable for most of the quaternization derivatives. The detailed SARs of diverse substituted
 91 benzyl group which varied in electron-inducing ability and substitution position were summarized
 92 in **Table 2**. In terms of halogen atom substitution, fluorine substituted benzyl groups are
 93 disadvantageous for improving the activity. Chlorine and iodine substituents may be better. In most
 94 instances, large sterically hindered groups such as methyl and trifluoromethyl are beneficial for
 95 activity enhancement. However, cyano and methoxy groups were exceptional and complex which
 96 need further study. Multiple substitutions showed different activity trends. Compound **6p** exhibited
 97 excellent antibacterial activity compared with agrochemical propineb.




Table 2. Structure–activity relationships against *R. solanacearum* and *P. syringae*.

Location	Bacteria strains	SARs
Ortho-position	<i>R. solanacearum</i>	F < Br = Me < Cl = CF ₃
	<i>P. syringae</i>	F = Br < Cl = Me = CF ₃
Meta-position	<i>R. solanacearum</i>	CN = OMe < F = Br < Cl = I = Me = CF ₃
	<i>P. syringae</i>	F = CN = CF ₃ < OMe = Br < Cl = I = Me
Para-position	<i>R. solanacearum</i>	F < Br = Me < CF ₃
	<i>P. syringae</i>	F < Br = CF ₃ < Me

98 3. Materials and Methods

99 3.1. General Details

100 All the reagents and solvents were obtained locally or purified according to standard methods.
 101 Melting points were determined using a digital melting-point apparatus and were uncorrected. ¹H
 102 NMR (500 MHz) and ¹³C NMR (125 MHz) spectra were recorded using a Bruker Avance III 500
 103 MHz instrument (Bruker, Madison, WI, USA) with TMS as the internal standard and
 104 dimethylsulfoxide (DMSO-*d*₆) as the solvent. High-resolution mass spectroscopy (HRMS) was
 105 undertaken using an AB SCIEX Triple TOF 5600+ spectrometer. The silica gel and GF254 silica gel of
 106 analytical thin-layer chromatography (TLC) were produced by the Qingdao Haiyang Chemical Co.,
 107 Ltd.,
 108

109 3.2. Synthesis of Target Compounds 6a–6v

110 The 10-methoxy canthin-6-one **5** could be easily obtained according to our previous work [15].
111 Compound **5** was dissolved in CH₃CN (50 mL) and the diverse substituted benzyl bromide or
112 chloride (5 eq.) was added. The solution was then stirred at 80 °C until the reaction is completed.
113 The reaction solution was concentrated under reduced pressure, and purified by flash column
114 chromatography using chloroform/methanol (30:1, *v/v*) as the eluent.

115 3-(2-Fluorobenzyl)-10-methoxy-6-oxo-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium bromide **6a**: yield
116 60%; yellow-green solid powder; m.p. 224.2–224.7 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.29 (d, *J* = 6.4
117 Hz, 1H), 8.96 (d, *J* = 6.4 Hz, 1H), 8.59 (d, *J* = 10.2 Hz, 1H), 8.43 (d, *J* = 9.0 Hz, 1H), 8.25 (d, *J* = 2.5 Hz, 1H),
118 7.57 (m, 1H), 7.51–7.46 (m, 1H), 7.40 (d, *J* = 10.2 Hz, 1H), 7.34 (m, 2H), 7.24 (d, *J* = 7.6 Hz, 1H), 6.39 (s,
119 2H), 3.96 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 158.7, 157.5, 142.6, 136.7, 136.3, 134.6, 134.5, 132.0,
120 131.9, 130.6, 130.2, 130.0, 125.7, 124.1, 122.8, 120.1, 117.9, 116.5, 116.3, 109.3, 58.6, 56.4. HRMS (ESI) *m/z*
121 calcd for C₂₂H₁₆BrFN₂O₂ [M–Br]⁺ 359.1190, found 359.1189.

122 3-(4-Fluorobenzyl)-10-methoxy-6-oxo-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium bromide **6b**: yield
123 61%; yellow-green solid powder; m.p. 233.2–235.0 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.32 (d, *J* = 6.4
124 Hz, 1H), 8.96 (d, *J* = 6.4 Hz, 1H), 8.60 (d, *J* = 10.2 Hz, 1H), 8.43 (d, *J* = 9.0 Hz, 1H), 8.27 (d, *J* = 2.6 Hz, 1H),
125 7.68 (m, 1H), 7.65–7.45 (m, 3H), 7.35 (m, 2H), 6.35 (s, 2H), 3.95 (s, 3H). HRMS (ESI) *m/z* calcd for
126 C₂₂H₁₆BrFN₂O₂ [M–Br]⁺ 359.1190, found 359.1188.

127 3-(3-Fluorobenzyl)-10-methoxy-6-oxo-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium bromide **6c**: yield
128 65%; brick yellow solid powder; m.p. 241.6–241.9 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.40 (d, *J* = 6.4
129 Hz, 1H), 9.00 (d, *J* = 6.4 Hz, 1H), 8.64 (d, *J* = 10.2 Hz, 1H), 8.40 (d, *J* = 9.0 Hz, 1H), 8.27 (d, *J* = 2.6 Hz, 1H),
130 7.65–7.45 (m, 3H), 7.38 (d, *J* = 10.2 Hz, 1H), 7.32–7.10 (m, 2H), 6.31 (s, 2H), 3.95 (s, 3H); ¹³C NMR (125
131 MHz, DMSO-*d*₆) δ 158.6, 157.5, 142.4, 136.5, 136.2, 134.6, 134.6, 131.3, 131.3, 130.6, 130.5, 130.3, 130.1,
132 124.1, 122.6, 120.2, 117.8, 116.5, 116.4, 109.3, 58.5, 56.6. HRMS (ESI) *m/z* calcd for C₂₂H₁₆BrFN₂O₂ [M–
133 Br]⁺ 359.1190, found 359.1190.

134 3-(3-Cyanobenzyl)-10-methoxy-6-oxo-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium chloride **6d**: yield
135 45%; brick red solid powder; m.p. 225.8–227.7 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.35 (d, *J* = 6.2 Hz,
136 1H), 8.99 (d, *J* = 6.2 Hz, 1H), 8.50 (d, *J* = 10.2 Hz, 1H), 8.43 (d, *J* = 9.0 Hz, 1H), 8.24 (d, *J* = 7.2 Hz, 1H),
137 7.91 (d, *J* = 8.0 Hz, 2H), 7.57 (d, *J* = 8.9 Hz, 1H), 7.53 (d, *J* = 8.0 Hz, 2H), 7.37 (d, *J* = 10.2 Hz, 1H), 6.42 (s,
138 2H), 3.96 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 158.7, 157.7, 142.4, 136.7, 136.3, 136.1, 134.7, 134.5,
139 133.8, 130.9, 130.8, 130.3, 128.9, 127.0, 126.1, 124.2, 122.7, 120.3, 118.0, 117.8, 109.4, 57.8, 56.6. HRMS (ESI)
140 *m/z* calcd for C₂₃H₁₆CIN₃O₂ [M–Cl]⁺ 366.1237, found 366.1235.

141 3-(2-Chlorobenzyl)-10-methoxy-6-oxo-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium chloride **6e**: yield
142 44%; yellow solid powder; m.p. 231.2–232.9 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.28 (d, *J* = 6.4 Hz,
143 1H), 9.02 (d, *J* = 6.4 Hz, 1H), 8.56 (d, *J* = 10.2 Hz, 1H), 8.40 (d, *J* = 9.0 Hz, 1H), 8.26 (d, *J* = 2.6 Hz, 1H),
144 7.97–7.65 (m, 1H), 7.59 (m, 1H), 7.42–7.28 (m, 3H), 6.88–6.78 (m, 1H), 6.34 (s, 2H), 3.95 (s, 3H); ¹³C NMR
145 (125 MHz, DMSO-*d*₆) δ 158.8, 157.6, 142.6, 139.9, 136.4, 136.3, 135.1, 134.6, 134.5, 130.3, 130.1, 129.5,
146 129.4, 127.9, 125.0, 124.1, 122.6, 120.2, 117.8, 109.5, 59.7, 56.6. HRMS (ESI) *m/z* calcd for C₂₂H₁₆Cl₂N₂O₂
147 [M–Cl]⁺ 375.0894, found 375.0892.

148 3-(3-Chlorobenzyl)-10-methoxy-6-oxo-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium chloride **6f**: yield 47%;
149 brick yellow solid powder; m.p. 229.5–231.2 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.38 (d, *J* = 6.4 Hz,
150 1H), 8.99 (d, *J* = 6.4 Hz, 1H), 8.57 (d, *J* = 10.2 Hz, 1H), 8.42 (d, *J* = 9.0 Hz, 1H), 8.26 (d, *J* = 2.6 Hz, 1H),
151 7.96–7.68 (m, 2H), 7.54 (m, 1H), 7.37 (d, *J* = 10.2 Hz, 1H), 7.22 (d, *J* = 8.4 Hz, 2H), 6.32 (s, 2H), 3.94 (s,
152 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 158.7, 157.5, 142.6, 136.7, 136.3, 134.6, 134.5, 132.0, 131.9, 130.9,
153 130.2, 130.0, 125.7, 124.1, 122.8, 120.1, 117.9, 116.5, 116.3, 109.3, 59.6, 56.4. HRMS (ESI) *m/z* calcd for
154 C₂₂H₁₆Cl₂N₂O₂ [M–Cl]⁺ 375.0894, found 375.0893.

155 10-Methoxy-3-(2-methylbenzyl)-6-oxo-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium bromide **6g**: yield
156 68%; brick yellow solid powder; m.p. > 280 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.18 (d, *J* = 6.4 Hz, 1H),
157 9.00 (d, *J* = 6.4 Hz, 1H), 8.44 (d, *J* = 8.9 Hz, 2H), 8.31 (d, *J* = 2.4 Hz, 1H), 7.57 (m, 1H), 7.38–7.33 (m, 2H),
158 7.28 (t, *J* = 7.4 Hz, 1H), 7.09 (t, *J* = 7.4 Hz, 1H), 6.55 (d, *J* = 7.7 Hz, 1H), 6.33 (s, 2H), 3.96 (s, 3H), 2.43 (s,
159 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 158.6, 157.7, 142.4, 136.7, 136.3, 136.0, 134.7, 134.5, 133.8, 130.9,

160 130.8, 130.3, 128.9, 127.0, 126.1, 124.2, 122.7, 120.3, 117.8, 109.4, 57.8, 56.6, 19.3. HRMS (ESI) m/z calcd
161 for $C_{23}H_{19}BrN_2O_2$ [M-Br]⁺ 355.1441, found 355.1439.

162 *10-Methoxy-3-(4-methylbenzyl)-6-oxo-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium bromide 6h*: yield
163 71%; yellow solid powder; m.p. 228.6–228.9 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.38 (d, *J* = 6.4 Hz,
164 1H), 8.98 (d, *J* = 6.4 Hz, 1H), 8.57 (d, *J* = 10.2 Hz, 1H), 8.35 (d, *J* = 9.0 Hz, 1H), 8.25 (d, *J* = 2.6 Hz, 1H),
165 7.49 (m, 1H), 7.34 (d, *J* = 10.2 Hz, 1H), 7.28 (t, *J* = 7.5 Hz, 1H), 7.18 (d, *J* = 9.2 Hz, 3H), 6.27 (s, 2H), 3.92 (s,
166 3H), 2.25 (s, 3H). HRMS (ESI) m/z calcd for $C_{23}H_{19}BrN_2O_2$ [M-Br]⁺ 355.1441, found 355.1439.

167 *10-Methoxy-3-(3-methylbenzyl)-6-oxo-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium bromide 6i*: yield
168 70%; yellow solid powder; m.p. 222.4–222.7 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.50 (d, *J* = 6.3 Hz,
169 1H), 9.03 (d, *J* = 6.3 Hz, 1H), 8.47 (d, *J* = 8.9 Hz, 2H), 8.32 (d, *J* = 2.4 Hz, 1H), 7.61 (m, 1H), 7.36–7.31 (m,
170 2H), 7.29 (t, *J* = 7.4 Hz, 1H), 7.12 (t, *J* = 7.5 Hz, 1H), 6.55 (d, *J* = 7.7 Hz, 1H), 6.35 (s, 2H), 3.98 (s, 3H), 2.43
171 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 158.7, 157.7, 142.6, 136.7, 136.3, 136.0, 134.7, 134.5, 133.8, 130.9,
172 130.8, 130.4, 128.9, 127.0, 126.1, 124.2, 122.7, 120.3, 117.9, 109.4, 59.8, 56.6, 21.4. HRMS (ESI) m/z calcd
173 for $C_{23}H_{19}BrN_2O_2$ [M-Br]⁺ 355.1441, found 355.1443.

174 *10-Methoxy-3-(3-methoxybenzyl)-6-oxo-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium chloride 6j*: yield
175 43%; brick yellow solid powder; m.p. 225.3–226.0 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.41 (d, *J* = 6.3
176 Hz, 1H), 8.97 (d, *J* = 6.3 Hz, 1H), 8.57 (d, *J* = 10.2 Hz, 1H), 8.39 (d, *J* = 9.0 Hz, 1H), 8.25 (d, *J* = 2.6 Hz, 1H),
177 7.46 (m, 1H), 7.34 (d, *J* = 10.2 Hz, 1H), 7.28 (t, *J* = 7.5 Hz, 1H), 7.18 (d, *J* = 9.2 Hz, 3H), 6.37 (s, 2H), 3.92 (s,
178 3H), 3.98 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 158.8, 157.6, 142.7, 136.6, 136.3, 136.2, 134.7, 134.7,
179 132.0, 130.7, 130.5, 130.3, 130.0, 126.1, 125.4, 124.1, 122.7, 120.3, 117.8, 109.4, 58.5, 56.5, 56.5. HRMS (ESI)
180 m/z calcd for $C_{23}H_{19}ClN_2O_3$ [M-Cl]⁺ 406.1078, found 355.1443.

181 *10-Methoxy-6-oxo-3-(2-(trifluoromethyl)benzyl)-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium bromide 6k*:
182 yield 70%; yellow solid powder; m.p. 243.6–244.1 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.22 (d, *J* = 6.4
183 Hz, 1H), 9.00 (d, *J* = 6.3 Hz, 1H), 8.47 (d, *J* = 9.0 Hz, 1H), 8.29 (t, *J* = 6.7 Hz, 2H), 7.96 (d, *J* = 7.6 Hz, 1H),
184 7.69–7.55 (m, 3H), 7.36 (d, *J* = 10.2 Hz, 1H), 6.82 (d, *J* = 7.8 Hz, 1H), 6.51 (s, 2H), 3.98 (s, 3H); ¹³C NMR
185 (125 MHz, DMSO-*d*₆) δ 158.6, 157.6, 142.6, 139.6, 136.7, 136.3, 134.7, 134.6, 130.5, 130.0, 129.8, 129.5,
186 128.6, 126.4, 125.5, 124.1, 123.3, 122.7, 120.3, 117.9, 109.4, 58.5, 56.6. HRMS (ESI) m/z calcd for
187 $C_{23}H_{16}BrF_3N_2O_2$ [M-Br]⁺ 409.1158, found 409.1155.

188 *10-Methoxy-6-oxo-3-(4-(trifluoromethyl)benzyl)-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium bromide 6l*:
189 yield 68%; yellow solid powder; m.p. 238.5–238.9 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.43 (d, *J* = 6.2
190 Hz, 1H), 9.01 (d, *J* = 6.2 Hz, 1H), 8.63 (d, *J* = 10.1 Hz, 1H), 8.41 (d, *J* = 8.9 Hz, 1H), 8.28 (d, *J* = 2.6 Hz, 1H),
191 7.92 (s, 1H), 7.77 (d, *J* = 5.2 Hz, 1H), 7.64 (s, 2H), 7.59–7.46 (m, 1H), 7.39 (d, *J* = 10.1 Hz, 1H), 6.43 (s, 2H),
192 3.95 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 158.6, 157.6, 142.6, 136.6, 136.3, 136.2, 134.8, 134.7, 132.0,
193 130.5, 130.0, 126.1, 125.4, 125.0, 124.1, 122.7, 120.3, 117.8, 109.4, 58.5, 56.6. HRMS (ESI) m/z calcd for
194 $C_{23}H_{16}BrF_3N_2O_2$ [M-Br]⁺ 409.1158, found 409.1159.

195 *10-Methoxy-6-oxo-3-(3-(trifluoromethyl)benzyl)-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium bromide*
196 **6m**: yield 72%; brick red solid powder; m.p. 223.3–223.7 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.38 (d, *J*
197 = 6.4 Hz, 1H), 8.99 (d, *J* = 6.4 Hz, 1H), 8.53 (d, *J* = 10.2 Hz, 1H), 8.40 (d, *J* = 9.0 Hz, 1H), 8.26 (d, *J* = 2.6 Hz,
198 1H), 7.77 (d, *J* = 8.3 Hz, 2H), 7.64–7.48 (m, 3H), 7.36 (d, *J* = 10.2 Hz, 1H), 6.42 (s, 2H), 3.93 (s, 3H); ¹³C
199 NMR (125 MHz, DMSO-*d*₆) δ 158.6, 157.6, 142.7, 139.7, 136.7, 136.2, 134.8, 134.73, 130.5, 130.0, 129.8,
200 129.5, 128.6, 126.4, 125.5, 124.1, 123.3, 122.7, 120.3, 117.9, 109.3, 58.6, 56.6. HRMS (ESI) m/z calcd for
201 $C_{23}H_{16}BrF_3N_2O_2$ [M-Br]⁺ 409.1158, found 409.1157.

202 *3-(2,5-Difluorobenzyl)-10-methoxy-6-oxo-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium bromide 6n*: yield
203 61%; yellow solid powder; m.p. 245.1–245.8 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.32 (d, *J* = 6.4 Hz,
204 1H), 8.99 (d, *J* = 6.3 Hz, 1H), 8.58 (d, *J* = 10.2 Hz, 1H), 8.43 (d, *J* = 9.0 Hz, 1H), 8.29 (d, *J* = 2.6 Hz, 1H),
205 7.57 (m, 1H), 7.50–7.29 (m, 3H), 7.20 (m, 1H), 6.39 (s, 2H), 3.95 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ
206 158.6, 157.6, 142.8, 136.8, 136.3, 134.7, 134.6, 130.7, 130.1, 124.2, 124.2, 124.1, 122.8, 120.2, 118.1, 117.9,
207 117.9, 116.6, 116.4, 109.4, 56.6, 53.9. HRMS (ESI) m/z calcd for $C_{22}H_{15}BrF_2N_2O_2$ [M-Br]⁺ 377.1096, found
208 377.1093.

209 *3-(2,4-Difluorobenzyl)-10-methoxy-6-oxo-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium bromide 6o*: yield
210 58%; yellow solid powder; m.p. 230.6–231.9 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.38 (d, *J* = 6.4 Hz,
211 1H), 8.98 (d, *J* = 6.4 Hz, 1H), 8.68 (d, *J* = 10.2 Hz, 1H), 8.43 (d, *J* = 9.0 Hz, 1H), 8.27 (d, *J* = 2.6 Hz, 1H),

212 7.58 (m, 1H), 7.64–7.45 (m, 3H), 7.38 (d, $J = 10.2$ Hz, 1H), 6.39 (s, 2H), 3.95 (s, 3H); ^{13}C NMR (125 MHz,
213 DMSO- d_6) δ 158.6, 157.6, 142.8, 136.7, 136.6, 134.6, 134.5, 130.6, 130.5, 124.2, 124.2, 124.1, 122.6, 120.2,
214 118.1, 117.9, 117.8, 116.6, 116.4, 109.3, 56.7, 53.9. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{15}\text{BrF}_2\text{N}_2\text{O}_2$ $[\text{M}-\text{Br}]^+$
215 377.1096, found 377.1094.

216 3-(3,4-Dichlorobenzyl)-10-methoxy-6-oxo-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium bromide **6p**: yield
217 46%; orange solid powder; m.p. 223.7–224.5 °C; ^1H NMR (500 MHz, DMSO- d_6) δ 9.40 (d, $J = 6.4$ Hz,
218 1H), 9.00 (d, $J = 6.4$ Hz, 1H), 8.60 (d, $J = 10.2$ Hz, 1H), 8.41 (d, $J = 9.0$ Hz, 1H), 8.29 (d, $J = 2.6$ Hz, 1H),
219 7.95–7.67 (m, 2H), 7.37 (d, $J = 10.2$ Hz, 1H), 7.22 (d, $J = 8.4$ Hz, 2H), 6.38 (s, 2H), 3.98 (s, 3H); ^{13}C NMR
220 (125 MHz, DMSO- d_6) δ 158.7, 157.5, 142.4, 136.5, 136.2, 134.6, 134.6, 131.3, 131.3, 130.6, 130.5, 130.3,
221 130.1, 124.1, 122.6, 120.2, 117.8, 116.5, 116.4, 109.3, 58.5, 56.6. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{15}\text{BrF}_2\text{N}_2\text{O}_2$
222 $[\text{M}-\text{Br}]^+$ 377.1096, found 377.1094.

223 3-(2-Bromobenzyl)-10-methoxy-6-oxo-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium bromide **6q**: yield
224 62%; brick yellow solid powder; m.p. 235.5–236.0 °C; ^1H NMR (500 MHz, DMSO- d_6) δ 9.20 (d, $J = 6.4$
225 Hz, 1H), 8.97 (d, $J = 6.4$ Hz, 1H), 8.46 (m, 2H), 8.28 (d, $J = 2.6$ Hz, 1H), 7.82 (m, 1H), 7.59 (m, 1H), 7.42–
226 7.28 (m, 3H), 6.88–6.78 (m, 1H), 6.34 (s, 2H), 3.96 (s, 3H); ^{13}C NMR (125 MHz, DMSO- d_6) δ 158.7, 157.6,
227 142.6, 136.9, 136.4, 134.7, 134.6, 134.2, 133.6, 131.2, 130.9, 130.2, 129.1, 129.0, 124.1, 122.8, 122.4, 120.2,
228 117.9, 109.4, 59.6, 56.6. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{16}\text{Br}_2\text{N}_2\text{O}_2$ $[\text{M}-\text{Br}]^+$ 419.0389, found 419.0390.

229 3-(4-Bromobenzyl)-10-methoxy-6-oxo-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium bromide **6r**: yield
230 65%; yellow solid powder; m.p. 234.5–235.2 °C; ^1H NMR (500 MHz, DMSO- d_6) δ 9.21 (d, $J = 6.4$ Hz,
231 1H), 8.92 (d, $J = 6.4$ Hz, 1H), 8.65 (m, 2H), 8.28 (d, $J = 2.6$ Hz, 1H), 7.86 (m, 1H), 7.79 (m, 1H), 7.39–7.24
232 (m, 3H), 7.13 (d, $J = 10.2$ Hz, 1H), 6.36 (s, 2H), 3.96 (s, 3H); ^{13}C NMR (125 MHz, DMSO- d_6) δ 158.7, 142.6,
233 136.8, 136.4, 134.7, 134.2, 133.8, 132.2, 130.5, 130.2, 129.4, 129.5, 124.1, 122.8, 122.4, 120.2, 117.9, 109.5,
234 59.6, 56.6. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{16}\text{Br}_2\text{N}_2\text{O}_2$ $[\text{M}-\text{Br}]^+$ 419.0389, found 419.0387.

235 3-(3-Bromobenzyl)-10-methoxy-6-oxo-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium bromide **6s**: yield
236 64%; brick red solid powder; m.p. 238.7–239.1 °C; ^1H NMR (500 MHz, DMSO- d_6) δ 9.30 (d, $J = 6.4$ Hz,
237 1H), 9.01 (d, $J = 6.4$ Hz, 1H), 8.47 (d, $J = 9.0$ Hz, 1H), 8.31 (t, $J = 6.7$ Hz, 2H), 7.76 (d, $J = 7.6$ Hz, 1H), 7.59–
238 7.45 (m, 3H), 7.16 (d, $J = 10.2$ Hz, 1H), 6.82 (d, $J = 7.8$ Hz, 1H), 6.51 (s, 2H), 3.98 (s, 3H); ^{13}C NMR (125
239 MHz, DMSO- d_6) δ 158.7, 157.5, 142.6, 136.7, 136.3, 134.6, 134.5, 132.0, 131.9, 130.9, 130.2, 130.0, 125.7,
240 124.1, 122.8, 120.1, 117.9, 116.5, 116.3, 109.3, 59.6, 56.4. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{16}\text{Br}_2\text{N}_2\text{O}_2$ $[\text{M}-$
241 $\text{Br}]^+$ 419.0389, found 419.0386.

242 3-(3-Iodobenzyl)-10-methoxy-6-oxo-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium bromide **6t**: yield 42%;
243 red solid powder; m.p. 245.6–246.3 °C; ^1H NMR (500 MHz, DMSO- d_6) δ 9.36 (d, $J = 6.4$ Hz, 1H), 8.99 (d,
244 $J = 6.4$ Hz, 1H), 8.57 (d, $J = 10.2$ Hz, 1H), 8.40 (d, $J = 9.0$ Hz, 1H), 8.26 (d, $J = 2.6$ Hz, 1H), 7.96–7.68 (m,
245 2H), 7.54 (m, 1H), 7.37 (d, $J = 10.2$ Hz, 1H), 7.22 (d, $J = 8.4$ Hz, 2H), 6.28 (s, 2H), 3.95 (s, 3H); ^{13}C NMR
246 (125 MHz, DMSO) δ ^{13}C NMR (126 MHz, DMSO- d_6) δ 158.6, 157.5, 142.5, 138.3, 136.6, 136.2, 134.8,
247 134.6, 134.6, 130.3, 130.2, 130.1, 124.1, 122.7, 120.2, 117.8, 116.5, 116.4, 109.3, 96.1, 58.7, 56.6. HRMS (ESI)
248 m/z calcd for $\text{C}_{22}\text{H}_{16}\text{BrIN}_2\text{O}_2$ $[\text{M}-\text{Br}]^+$ 467.0251, found 467.0251.

249 3-Benzyl-10-methoxy-6-oxo-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium bromide **6u**: yield 65%; yellow
250 solid powder; m.p. 224.1–224.5 °C; ^1H NMR (500 MHz, DMSO- d_6) δ 9.40 (d, $J = 6.4$ Hz, 1H), 8.99 (d, $J =$
251 6.2 Hz, 1H), 8.60 (d, $J = 10.2$ Hz, 1H), 8.40 (d, $J = 9.0$ Hz, 1H), 8.26 (d, $J = 2.3$ Hz, 1H), 7.54 (m, 1H), 7.51–
252 7.29 (m, 6H), 6.32 (s, 2H), 3.94 (s, 3H). HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{17}\text{BrN}_2\text{O}_2$ $[\text{M}-\text{Br}]^+$ 341.1284, found
253 341.1282.

254 3-Benzyl-10-methoxy-6-oxo-6H-indolo[3,2,1-de][1,5]naphthyridin-3-ium chloride **6v**: yield 56%; yellow
255 solid powder; m.p. 222.4–222.9 °C; ^1H NMR (500 MHz, DMSO- d_6) δ 9.38 (d, $J = 6.4$ Hz, 1H), 9.01 (d, $J =$
256 6.4 Hz, 1H), 8.58 (d, $J = 10.2$ Hz, 1H), 8.40 (d, $J = 9.0$ Hz, 1H), 8.28 (d, $J = 2.3$ Hz, 1H), 7.56 (m, 1H), 7.50–
257 7.27 (m, 6H), 6.33 (s, 2H), 3.96 (s, 3H). HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{17}\text{ClN}_2\text{O}_2$ $[\text{M}-\text{Br}]^+$ 341.1284, found
258 341.1280.

259 3.3. Antibacterial assay

260 MICs were determined as described by the National Committee for Clinical Laboratory
261 Standards [19]. *B. cereus* (CGMCC 1.1846) was purchased from the China General Microbiological
262 Culture Collection Center. *R. solanacearum* and *P. syringae* were provided by the College of Plant

263 Protection, Northwest A&F University [20]. The MIC was defined as the minimum inhibitory
264 concentration, each compound resulting in visible inhibition on bacteria growth (incubation at 37 °C
265 for 12–14 h). Each bacterial suspension was adjusted to a concentration of 1×10^5 CFU/mL. All
266 compounds were thoroughly dried before weighing. Initially, the compounds were dissolved in
267 dimethyl sulfoxide (DMSO) to prepare the stock solutions. The tested compounds (5 and 6a–6v) and
268 reference drugs were then prepared in liquid Luria–Bertani media. The required concentrations were
269 125, 62.5, 31.25, 15.63, 7.81, 3.91 and 1.95 $\mu\text{g/mL}$, respectively (DMSO < 0.5%).

270 4. Conclusions

271 In this study, twenty-two new quaternarization 10-methoxycanthin-6-one derivatives were
272 designed and synthesized based on our previous work. Their antibacterial activity was evaluated
273 against three bacterial strains including two kinds of agricultural pathogenic bacteria. Four
274 compounds (6f, 6i, 6p and 6t) displayed 2-fold superiority (MIC = 3.91 $\mu\text{g/mL}$) against *R.*
275 *solanacearum* and *P. syringae* than agrochemical propineb. Simultaneously, the structure–activity
276 relationships were summarized which provided some important guidance for the development of
277 antibacterial agents. Overall, this work further demonstrated here the antibacterial potential of
278 canthin-6-one scaffold, enriched the types of candidate antibiotics and provided more options for
279 solving the issue of “lack of antibiotics”.

280 **Author Contributions:** N. Li. conceived and designed this work; J.-R. Wang and J.-Y. Wang wrote the paper.

281 **Funding:** This work was funded by the National Natural Science Foundation of China (Grant No. 81773603).

282 **Conflicts of Interest:** The authors declare no conflict of interest.

283 References

- 284 1. Laxminarayan, R.; Duse, A.; Wattal, C.; Zaidi, A.K.M.; Wertheim, H.F.L.; Sumpradit, N.; Vlieghe, E.; Hara,
285 G.L.; Gould, I.M.; Goossens, H.; Greko, C.; So, A.D.; Bigdeli, M.; Tomson, G.; Woodhouse, W.; Ombaka, E.;
286 Peralta, A.Q.; Qamar, F.N.; Mir, F.; Kariuki, S.; Bhutta, Z.A.; Coates, A.; Bergstrom, R.; Wright, G.D.;
287 Brown, E.D.; Cars, O. Antibiotic resistance—the need for global solutions. *Lancet. Infect. Dis.* **2013**, *13*,
288 1057–1098.
- 289 2. Economou, V.; Gousia, P. Agriculture and food animals as a source of antimicrobial-resistant bacteria.
290 *Infect. Drug Resist.* **2015**, *8*, 49–61.
- 291 3. Pal, C.; Bengtsson-Palme, J.; Kristiansson, E.; Larsson, D.G.J. The structure and diversity of human, animal
292 and environmental resistomes. *Microbiome* **2016**, *4*, 54.
- 293 4. Walsh, T.R.; Efthimiou, J.; Dréno, B. Systematic review of antibiotic resistance in acne: an increasing
294 topical and oral threat. *Lancet. Infect. Dis.* **2016**, *16*, e23–e33.
- 295 5. O'Neill, J. Tackling drug-resistant infections globally: final report and recommendations. Review on
296 antimicrobial resistance. **2016**, Government of the UK. <http://apo.org.au/node/63983>.
- 297 6. Helgason, E.; Økstad, O.A.; Caugant, D.A.; Johansen, H.A.; Fouet, A.; Mock, M.; Hegna, I.; Kolstø, A.B.
298 *Bacillus anthracis*, *Bacillus cereus*, and *Bacillus thuringiensis*—One species on the basis of genetic evidence.
299 *Appl. Environ. Microb.* **2000**, *66*, 2627–2630.
- 300 7. Salanoubat, M.; Genin, S.; Artiguenave, F.; Gouzy, J.; Mangenot, S.; Arlat, M.; Billault, A.; Brottier, P.;
301 Camus, J.; Cattolico, L. Genome sequence of the plant pathogen *Ralstonia solanacearum*. *Nature* **2002**, *415*,
302 497–502.
- 303 8. Wright, J.D. Opportunities for natural products in 21st century antibiotic discovery. *Nat. Prod. Rep.* **2017**,
304 *34*, 694–701.
- 305 9. Butler, M.S.; Robertson A.A.B.; Cooper M.A. Natural product and natural product derived drugs in
306 clinical trials. *Nat. Prod. Rep.* **2014**, *31*, 1612–1661.
- 307 10. Dai, J.K., Li, N.; Wang, J.R.; Schneider, U. Fruitful decades for canthin-6-ones from 1952 to 2015:
308 biosynthesis, chemistry, and biological activities. *Molecules* **2016**, *21*, 493.
- 309 11. Dai, J.K.; Dan, W.J.; Schneider, U.; Wang, J.R. β -Carboline alkaloid monomers and dimers: Occurrence,
310 structural diversity, and biological activities. *Eur. J. Med. Chem.* **2018**, *157*, 622–656.
- 311 12. Dai, J.K.; Dan, W.J.; Li, N.; Du, H.T.; Zhang, J.W.; Wang, J.R. Synthesis, in vitro antibacterial activities of a
312 series of 3-N-substituted canthin-6-ones. *Bioorg. Med. Chem. Lett.* **2016**, *26*, 580–583.

- 313 13. Dai, J.K.; Dan, W.J.; Ren, S.Y.; Shang, C.G.; Wang, J.R. Design, synthesis and biological evaluations of
314 quaternization harman analogues as potential antibacterial agents. *Eur. J. Med. Chem.* **2018**, *160*, 23-36.
- 315 14. Dai, J.K.; Dan, W.J.; Zhang, Y.Y.; He, M.F.; Wang, J.R. Design and synthesis of C¹⁰ modified and
316 ring-truncated canthin-6-one analogues as effective membrane-active antibacterial agents. *Bioorg. Med.*
317 *Chem. Lett.* **2018**, *28*, 3123-3128.
- 318 15. Zhao, F.; Dai, J.K., Li, D.; Wang, S.J.; Wang, J.R. Synthesis and evaluation of ester derivatives of
319 10-hydroxycanthin-6-one as potential antimicrobial agents. *Molecules* **2016**, *21*, 390.
- 320 16. Dai, J.K.; Dan, W.J.; Li, N.; Wang, J.R. Computer-aided drug discovery: novel 3,9-disubstituted eudistomin
321 U derivatives as potent antibacterial agents. *Eur. J. Med. Chem.* **2018**, *157*, 333-338.
- 322 17. Dai, J.K.; Dan, W.J.; Li, N.; Wang, R.X.; Zhang, Y.; Li, N.N.; Wang, R.Z.; Wang, J.R. Synthesis and
323 antibacterial activity of C² or C⁵ modified and D ring rejiggered canthin-6-one analogues. *Food Chem.* **2018**,
324 *253*, 211-220.
- 325 18. Bazina, L.; Maravić, A.; Krce, L.; Soldo, B.; Odžak, R.; Popović, V.B.; Aviani, L.; Primožič, L.; Šprung, M.
326 Discovery of novel quaternary ammonium compounds based on quinuclidine-3-ol as new potential
327 antimicrobial candidates. *Eur. J. Med. Chem.* **2019**, *163*, 626-635.
- 328 19. *Performance Standards for Antimicrobial Susceptibility Testing; 11th Informational Supplement*; National
329 Committee for Clinical Laboratory Standards: Wayne, PA; Vol. 21, No. 1, M100-S11.
- 330 20. Dan, W.J.; Geng, H.L.; Qiao, J.W.; Guo, R.; Wei, S.P.; Li, L.B.; Wu, W.J.; Zhang, J.W. Efficient synthesis and
331 antibacterial evaluation of (±)-Yanglingmycin and its analogues. *Molecules* **2016**, *21*, 96.

332 **Sample Availability:** Samples of all the compounds in this paper are available from the authors.

333